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In fibrotic diseases caveolin-1 underexpression in fibroblasts results in collagen
overexpression and in monocytes leads to hypermigration. These profibrotic behaviors
are blocked by the caveolin-1 scaffolding domain peptide (CSD) which compensates for
caveolin-1 deficiency. Monocytes and fibroblasts are related in that monocytes are the
progenitors of fibrocytes (CD45+/Collagen I+ cells) that, in turn, are the progenitors
of many fibroblasts in fibrotic tissues. In an additional anti-fibrotic activity, CSD blocks
monocyte differentiation into fibrocytes. We studied a mouse fibrosis model (PumpModel)
involving systemic bleomycin delivery that closely models scleroderma (SSc) in several
ways, the most important of which for this study is that fibrosis is observed in the lungs,
skin, and internal organs. We show here that dermal thickness is increased 2-fold in
the Pump Model and that this effect is almost completely blocked by CSD (p < 0.001).
Concomitantly, the subcutaneous fat layer becomes >80% thinner. This effect is also
blocked by CSD (p < 0.001). Even in mice receiving vehicle instead of bleomycin, CSD
increases the thickness of the fat layer. To study the mechanisms of action of bleomycin
and CSD, we examined the accumulation of the chemokine receptor CCR5 and its ligands
MIP1α and MIP1β in fibrotic tissue and their roles in monocyte migration. Fibrocytes
and other leukocytes expressing CCR5 and its ligands were present at high levels in
the fibrotic dermis of SSc patients and Pump Model mice while CSD blocked their
accumulation in mouse dermis. Migration toward CCR5 ligands of SSc monocytes and
Pump Model bone marrow cells was 3-fold greater than cells from control subjects. This
enhanced migration was almost completely blocked by CSD. These results suggest that
low monocyte caveolin-1 promotes fibrosis by enhancing the recruitment of fibrocytes and
their progenitors into affected tissue.
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INTRODUCTION
Skin is usually the most involved organ in systemic sclerosis (scle-
roderma, SSc). Fibrotic lesions characterized by thickened dermis,
enlarged follicles, and obliterated blood vessels initially involve
the reticular dermis, then spread to the adjacent adipose layer and
ultimately to internal organs (Altman et al., 1991; Silver, 1995).
Diffuse cutaneous SSc describes the most severe form of the skin
disease which is particularly likely to spread to internal organs and
result in death (Abraham and Varga, 2005).
While historically it was believed that fibrosis results from
the activation by cytokines of resident fibroblasts into myofi-
broblasts that overexpress collagen, recent studies suggest that
fibroblasts can also be derived from other cell types including:
(1) Bone marrow-derived cells, (2) Epithelial cells via epithelial-
mesenchymal transformation, and (3) Pericytes (Hung et al.,
2013). We are particularly interested in the bone marrow lineage
in which monocytes differentiate into fibrocytes (recognized by
their co-expression of hematopoietic markers such as CD45 and
mesenchymal markers such as collagen (I) which in turn differen-
tiate into fibroblasts. Fibrocytes or their precursors are recruited
into target tissues by chemokines present at high concentration
that create a chemotactic gradient. The ability of cells to sense
the chemotactic gradient depends on the presence of appropriate
chemokine receptors on the cell surface. In addition to their role
as precursors of fibroblasts, fibrocytes also participate in fibrosis
by releasing a variety of cytokines and chemokines (e.g., TGF-β,
MCP-1, MIP1α, MIP1β) (Chesney et al., 1998) and angiogenic
factors (e.g., VEGF, PDGF-A, and IL-1β) (Hartlapp et al., 2001).
It is noteworthy that fibrocytes secrete chemokines that recruit
additional fibrocytes into fibrotic tissue.
Observations on multiple cell types including fibroblasts and
monocytes frompatients and from animal models have suggested
that a common feature of fibrotic diseases is the underexpres-
sion of caveolin-1, a protein that acts as a master regulator of
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several signaling pathways by binding to and thereby inhibiting
the function of multiple kinases (Tourkina et al., 2005, 2008,
2010, 2011; Wang et al., 2006). Likewise, the skin and lungs of
caveolin-1 null mice are fibrotic (Del Galdo et al., 2008). Using
both in vitro and in vivo assays, we demonstrated that when the
caveolin-1 scaffolding domain peptide (CSD, amino acids 82-101
of caveolin-1) is introduced into cells, it mimics the function of
full-length caveolin-1 and thereby reverses the pathological effects
of caveolin-1 deficiency such as collagen overexpression by fibrob-
lasts, the hypermigration of monocytes toward CXCL12 in vitro
and into damaged lung tissue in vivo, and enhanced monocyte
differentiation into fibrocytes (Tourkina et al., 2005, 2008, 2010,
2011). The fact that in fibrosis both fibroblasts and monocytes are
deficient in caveolin-1 is intriguing because monocytes differen-
tiate into fibrocytes which in turn differentiate into fibroblasts.
Thus cells derived from circulating monocytes may participate
in fibrosis in a variety of target organs. By targeting mono-
cyte/fibrocyte recruitment and fibrocyte differentiation, CSDmay
serve as a useful treatment for fibrotic diseases in a wide range of
tissues.
The role of the chemokine receptor CCR5 in pulmonary
fibrosis is particularly striking. CCR5 KO mice are resistant to
bleomycin-induced pulmonary fibrosis in terms of tissue mor-
phology and of collagen and fibrocyte accumulation in the tissue
(Ishida et al., 2007). Moreover, in reconstitution experiments KO
bone marrow was sufficient to provide protection in otherwise
wild typemice while wild type bonemarrowwas sufficient to pro-
vide sensitivity in otherwise KOmice (Ishida et al., 2007), strongly
supporting the ideas that bone marrow-derived cells (i.e., fibro-
cytes) are important players in the development of fibrosis in vivo
and that CCR5 is a key regulator of their behavior. The levels of
CCR5 and its ligands present support the idea that these are also
important players in SSc and other human fibrotic diseases. CCR5
ligands are present at high levels in the serum and in affected tis-
sues in SSc patients (Bolster et al., 1997; Hasegawa et al., 1999;
Codullo et al., 2011; Gambichler et al., 2011, 2012; Bandinelli
et al., 2012). Levels of CCR5 and its ligands in bronchoalveo-
lar lavage fluid from patients with idiopathic pulmonary fibrosis
(IPF) are significantly elevated (Capelli et al., 2005). CCR5 has
also been identified as an essential mediator in hepatic fibrosis
(Seki et al., 2009; Berres et al., 2010; Nellen et al., 2012; Stock et al.,
2013) through regulating macrophage and fibrocyte infiltration.
Recently, we found that systemic bleomycin delivery using sub-
cutaneously implanted osmotic minipumps can produce a very
useful mouse model for SSc in which fibrosis is observed in the
skin, lungs, and a variety of other internal organs (Lee et al.,
2014). In the current study, the ability of CSD to block the pro-
gression of skin fibrosis in this model has been examined with
particular emphasis on the role of CCR5. We find that CSD
blocks the induction by bleomycin of dermal fibrosis while also
blocking the accumulation of fibrocytes, CCR5, and CCR5 lig-
ands in the skin. The importance of these findings to human
fibrotic disease was validated by the observations that fibrocytes,
CCR5, and CCR5 ligands accumulate in the fibrotic skin of SSc
patients and that CSD blocks the migration of SSc monocytes
toward CCR5 ligands. Interestingly, we also observed that, in this
model, bleomycin caused a major decrease in the thickness of
the subcutaneous adipocyte layer and that this effect, like dermal
thickening, was also reversed by CSD. To the best of our knowl-
edge, this is the first report on the ability of CSD to block the
progression of dermal fibrosis and restore the adipose tissue layer
in vivo.
MATERIALS AND METHODS
PUMP MODEL FOR SYSTEMIC BLEOMYCIN TREATMENT
The following procedures were approved by the MUSC
Institutional Animal Care and Use Committee. Ten-week old,
male CD1 mice (Charles River Laboratories, Boston, MA) main-
tained under pathogen-free conditions were treated systemi-
cally with bleomycin (Teva Parenteral Medicines, Inc., Irvine,
CA) using an approach we refer to as the Pump Model. In
this model, osmotic minipumps (ALZET 1007D; DURECT
Corporation, Cupertino, CA) containing either 100μl saline
vehicle or bleomycin (100 U/kg) designed to deliver their contents
at 0.5μl/h for 7 days were implanted under isofluorane anesthesia
under the loose skin on the back of the mice slightly posterior to
the scapulae. Pumps were removed on day 10 as recommended by
the manufacturer. Each experiment was performed using at least
six mice per group. In experiments involving CSD, starting the
day before pump implantation, mice were injected i.p. daily for
28 days with 100μl of CSD peptide (concentration 0.1mM) or of
vehicle (10% DMSO in water). CSD was synthesized as a fusion
protein to the C terminus of the Antennapedia Internalization
Sequence as previously described (Tourkina et al., 2008).
Mice were routinely sacrificed by cervical dislocation under
isoflurane anesthesia on day 28 or at earlier times as indicated.
Under deep anesthesia, the rib cage was opened to expose the tho-
racic cavity. Mice to be analyzed by histology or immunohistology
were systemically perfused via the left ventricle sequentially with
PBS and buffered zinc formalin fixative (Z-Fix, Anatech, Battle
Creek, MI). Lower back skin tissue near the implanted pump was
then removed and embedded in paraffin. Sections (4μm) were
stained with hematoxylin and eosin (H&E) orMasson’s trichrome
or immunohistochemically as described below.
To isolate bone marrow cells for use in cell migration experi-
ments, following PBS perfusion femurs and tibiae were carefully
cleaned from the adherent soft tissue. The tip of each bone was
removed with a rongeur, and the marrow was harvested by insert-
ing a syringe needle (27-gauge) into one end of the bone, and
flushing with Dulbecco’s Modified Eagle Medium (DMEM). The
bone marrow cells were then filtered through a 70-mm nylon
mesh filter (BD Falcon, USA) and counted.
HISTOPATHOLOGICAL ASSESSMENT OF MOUSE SKIN FIBROSIS
Morphologic characteristics of skin sections were assessed under
a light microscope. The dermal thickness was defined as the dis-
tance from the top of the granular layer to the junction between
the dermis and subcutaneous fat and was measured by a blinded
observer.
HUMAN BLOOD AND SKIN DONORS
Under a protocol approved by the Institutional Review Board for
Human Research, patients with SSc and interstitial lung disease
(ILD) were recruited from the Scleroderma Clinic at the Medical
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University of South Carolina (MUSC). All patients fulfilled the
American College of Rheumatology (formerly the American
Rheumatism Association) criteria for SSc (Subcommittee, 1980).
A written consent was obtained from all studied subjects.
Demographic and clinical characteristics of human subjects
are summarized in Tables 1, 2. Systemic sclerosis patients were
classified as having either limited cutaneous (lcSSc) or diffuse
cutaneous (dcSSc) systemic sclerosis according to the criteria pro-
posed by LeRoy et al. (1988). Disease duration was determined
based on when the first non-Raynaud phenomenon symptoms
were documented. The following criteria were used to define
visceral involvement:
Pulmonary
Demonstration of abnormalities on high resolution computed
tomographic (HRCT) scan (ground glass changes and/or fibro-
sis), pulmonary hypertension based on a right heart catheter-
ization, restrictive changes on pulmonary function testing, or
reduced diffusing capacity for carbon monoxide.
Gastrointestinal (GI)
History of gastro-esophageal reflux disease based on either sub-
jective and/or objective findings. Some patients had symptoms of
reflux requiring treatment with a proton pump inhibitor and/or
H2-antagonist. Others had abnormal motility documented by
Table 1 | Clinical features of SSc patients and control subjects involved in monocyte experiments.
SSc (n = 11) Controls (n = 20)
Age Mean ± SD (years) 54.2 ± 10.9 40.7 ± 12.9
Range (years) 37–69 18–55
Disease duration Mean ± SD (years) 5.7 ± 5.3
Range (years) 1–16
Number (%) Number (%)
Race Caucasian (male) 2 (18.2) 3 (15.0)
Caucasian (female) 4 (36.4) 7 (35.0)
African-American (male) 3 (27.3) 2 (10.0)
African-American (female) 3 (27.3) 8 (40.0)
Smoking status Smoker 0 (0) 1 (5.0)
Former smoker 1 (9.1) 1 (5.0)
Diagnosis Limited cutaneous 6 (54.6)
Diffuse cutaneous 5 (45.5)
Overlap 1 (9.1)
Symptoms Pulmonary involvement (ILD) 7 (63.6)
Pulmonary hypertension 1 (9.1)
Gastrointestinal involvement 1 (9.1)
Cardiac involvement 2 (18.2)
Renal involvement 1 (9.1)
Raynaud phenomenon 11 (100)
Autoantibodies Antinuclear antibodies 11 (100)
Anti-topoisomerase I 4 (36.4)
Anti-centromere 0 (0)
Table 2 | Clinical features of SSc patients providing skin biopsies.
SSc (n = 4) Controls (n = 6)
Age Mean ± SD (years) 62.0 ± 11.4 56.7 ± 12.4
Range (years) 45–69 44–69
Disease duration Mean ± SD (years) 4.7 ± 2.9
Range (years) 8–16
Number (%) Number (%)
Race Caucasian (male) 0 (0) 0 (0)
Caucasian (female) 4 (100) 4 (66.7)
African-American (male) 0 (0) 0 (0)
African-American (female) 0 (0) 2 (33.3)
Smoking status Smoker 0 (0) 0 (0)
Former smoker 0 (0) 0 (0)
www.frontiersin.org June 2014 | Volume 5 | Article 140 | 3
Lee et al. Caveolin-1 regulates CCR5-mediated dermal fibrosis
esophageal manometry or findings of esophagitis on upper
endoscopy.
Cardiac
Evidence on echocardiogram of left ventricular diastolic dys-
function, a pericardial effusion, elevated peak right ventricular
systolic pressure, right ventricular and/or right atrial dilatation.
Conduction abnormalities on a 12—lead EKG was also consid-
ered sufficient.
Renal
History of rapidly progressive renal failure.
Autoantibodies
Antinuclear antibodies (ANA) and anti-centromere antibodies
were determined by immunofluorescent analysis on Hep-2 cell
substrates. Anti-Scl-70 (topoisomerase I) antibodies were deter-
mined by enzyme immunoassay.
HISTOPATHOLOGY OF HUMAN SKIN
Skin biopsy tissue from eight human subjects (four patients with
SSc and four healthy controls) were fixed withbuffered zinc for-
malin (Z-Fix, Anatech, Battle Creek, MI), paraffin embedded and
sectioned (4μm), and stained with H&E or Masson’s trichrome
or immunohistochemically as described below.
HUMANMONOCYTE ISOLATION
Human monocytes were isolated using standard protocols
(Tourkina et al., 2010, 2011). Following centrifugation on density
1.083 Histopaque cushions to isolate peripheral blood mononu-
clear cell (PBMC), monocytes were then isolated from the PBMC
by immunodepletion using a Dynal Monocyte Negative Isolation
Kit (Invitrogen, Carlsbad, CA) resulting in a cell population of
95%Mac-1+ monocytes.
MONOCYTE MIGRATION
Monocytemigrationassays were performed as previously
described (Tourkina et al., 2011). Briefly, chemokine ligands
(100 nM of MIP1α or MIP1β in RPMI 1640 with 1% BSA)
were placed into the lower wells of Neuro Probe Multiwell
Chemotaxis Chambers (Neuro Probe, Gaithersburg, MD) fitted
with 5μm pore size polycarbonate filters. 25μl of cell suspen-
sion (1× 106 cells/ml) with or without TGF-β pretreatment
(45min, 10 ng/ml in RPMI 1640 with 1% BSA) was placed in
the upper wells. CSD peptide (0.1μM) or control peptide was
added to cells before they were placed in the upper chamber.
After incubation for 2.5 h at 37◦C in a 5% CO2 incubator,
the filters separating the upper and lower wells were removed,
fixed, and stained with DAPI. Cells on the underside of the
membrane were counted in six high power (400×) fields per
filter.
IMMUNOHISTOCHEMISTRY
Immunofluorescent staining of mouse and human skin tis-
sue sections was performed (Tourkina et al., 2008) using
routine methods. Fluorescent images were acquired using a
Zeiss Axio Imager M2 fluorescence microscopy (Carl Zeiss,
Germany).
STATISTICAL ANALYSES
Numerical data are expressed as average ± s.e.m. and were ana-
lyzed using ANOVA with post-hoc Tukey’s test to evaluate statis-
tical significance. In all figures, statistical significance is expressed
as ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
ANTIBODIES AND CHEMOKINES USED
eBioscience (San Diego, CA): Mouse anti-human CD45 (14-
0459). Santa Cruz Biotechnology (Dallas, TX): Rabbit anti-
caveolin-1 (sc-894). EMD Millipore (Billerica, MA): Rat
anti-human procollagen I (MAB1912); Mouse anti-human pro-
collagen I (MAB1912); Rabbit monoclonal anti-fatty acid bind-
ing protein 4 (FABP4) (MABS172). GTx Inc (Memphis, TN),
anti-CCR5 (GTX61751). BD Biosciences (San Jose, CA): Rat
anti-mouse CD45 (553076). Bioss Antibodies (Woburn, MA):
Rabbit anti-MIP1α (bs-1045R); Rabbit anti-MIP1β (bs-2475R).
In some cases primary antibodies were directly labeled using an
Alexa Fluor 647 Protein Labeling Kit (Invitrogen, Carlsbad, CA,
A-20173) as described by the manufacturer. In other cases, appro-
priate fluorescent secondary antibodies were used. Nuclei were
routinely stained using 4′, 6-diamidino-2-phenylindole (DAPI)
(Invitrogen). All immunohistochemical experiments were per-
formed at least three times with similar results. Chemokines
were obtained from Peprotech (Rocky Hill, NJ): Human MIP1α
(300-08); Human MIP1β (300-09).
RESULTS
VALIDATION OF A BLEOMYCIN-INDUCED MURINE MODEL FOR SKIN
FIBROSIS
We recently compared two methods of delivering bleomycin
[Direct Model (directly into the lungs) and Pump Model (sys-
temic delivery using implanted osmotic minipumps)]and found
that the lung disease induced in the Pump Model was distinct
from the disease induced in the Direct Model and more sim-
ilar to the lung disease observed in SSc patients (Lee et al.,
2014). Relevant to the current study, the Pump Model was also
more similar to SSc in that dermal fibrosis was observed in
the Pump Model (Figure 1), but not in the Direct Model (not
shown). Dermal thickness showed a time-dependent increase in
bleomycin-treated mice (Figure 1). By 10 days after treatment, a
statistically significant increase in dermal thickness had occurred.
By day 28 dermal thickness had increased to about 2-fold the level
in control mice.
Fibrosis was also observed in the dermis of SSc patients. While
the available tissue sections were not full-thickness and thus did
not allow us to quantify the thickness of the dermis,images of SSc
skin (particularly at higher magnification) revealed that collagen
fibrils were packed more densely than in control skin (Figure 2).
Interestingly, as in SSc patients (Marangoni et al., 2012), lipodys-
trophy (a loss of the subcutaneous adipose cell layer) was also
observed in bleomycin-treated mice (Figure 1).
CSD BLOCKS BLEOMYCIN-INDUCED DERMAL FIBROSIS AND
LIPODYSTROPHY
We previously demonstrated that CSD can block bleomycin-
induced lung fibrosis in the Direct Model (Tourkina et al., 2008).
Here we demonstrate that CSD can also block bleomycin-induced
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FIGURE 1 | Bleomycin-induced dermal fibrosis. As described in the
Methods, osmotic minipumps were used to deliver bleomycin or saline
vehicle systemically to 10 week old male CD1 mice. Mice were sacrificed
on days 10, 21, or 28. Lower back skin tissue near the implanted pump was
harvested, paraffin sections cut and stained with H&E or Masson’s
trichrome (MT), and the thickness of the dermis measured (arrows).
(A) Representative images. 100μm bars are present in each panel.
(B) Measurements (average ± s.e.m.) from six mice per category, six sites
per mouse. Bleomycin induced significant dermal fibrosis as evidenced by
increased dermal thickness and lipodystropy as evidenced by loss of the
adipose cell layer.
skin fibrosis in the Pump Model (Figure 3). While CSD has no
effect on dermal thickness in mice treated with saline vehicle,
it almost completely blocks bleomycin-induced dermal thicken-
ing (Figures 3A,B). CSD also reversed the lipodystrophy induced
by bleomycin treatment (Figures 3A,C). In addition, CSD caused
FIGURE 2 | Histopathology of skin lesions in SSc patients. Skin
sections from Control subjects and SSc patients were stained with H&E
or Masson’s Trichrome (MT). 100μm bars are present in each
low-magnification panel (top two rows). High-magnification MT images
with 50μm bars (third row) expand on the boxed regions in the
low-magnification MT images. Note that collagen fibrils are packed more
densely in SSc skin than in Control skin. Similar results were observed in
four subjects in each category.
a striking increase in the thickness of the adipose cell layer in
control mice treated with saline vehicle.
INCREASED ACCUMULATION OF FIBROCYTES AND CELLS POSITIVE
FOR CCR5 AND ITS LIGANDS IN FIBROTIC SKIN
To confirm that fibrocytes are important players in fibrosis,
we determined fibrocyte levels in fibrotic human and mouse
skin. CD45+/Procollagen I+ cells (i.e., fibrocytes) were detected
at levels >5-fold higher in the fibrotic dermis of SSc patients
(Figures 4C,D) and Pump Model mice (Figure 5B) than in con-
trol dermis where almost no fibrocytes were present. CCR5 has
been shown to be a chemokine receptor of central importance in
lung fibrosis (Ishida et al., 2007). To begin to determine the role
of CCR5 in skin fibrosis, human and mouse skin sections were
double-stained for CCR5 and either Procollagen I (Figures 4A,B)
or CD45 (Figures 4E,F). Again, a similar >5-fold increase in
double-positive cells was observed in all cases in fibrotic tissue,
strongly suggesting that the fibrocytes present in fibrotic dermis
are CCR5+.
To evaluate the accumulation in fibrotic skin of cells positive
for CCR5 ligands, we double-stained human and mouse dermis
for CD45 and for either MIP1α or MIP1β. CCR5 ligand-positive
cells were detected at >5-fold higher levels in the fibrotic der-
mis of SSc patients (Figure 6) and Pump Model mice (Figure 7)
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FIGURE 3 | CSD blocks dermal fibrosis and subcutaneous
lipodystrophy. As described in the Methods, osmotic minipumps were
used to deliver bleomycin or saline vehicle systemically to 10-week old
male CD1 mice. As indicated, mice also were injected daily i.p with 100μl
of CSD (concentration 0.1mM) or of vehicle. Mice were sacrificed on day
28. Lower back skin tissue near the implanted pump was harvested,
paraffin sections cut and stained with H&E or Masson’s trichrome (MT),
and the thickness of the dermis and adipose cell layer measured.
(A) Representative images showing increased dermal thickness and
thinning of the adipose cell layer in bleomycin-treated mice, both of which
are blocked by CSD. Images of saline-treated Control mice show that CSD
does not affect dermal thickness, but greatly increases the thickness of
the adipose cell layer. 100μm bars are present in each panel. (B,C)
Measurements (average ± s.e.m.) from six mice per category, six sites
per mouse. (B) Quantification of (A) for dermal thickness; (C)
Quantification of (A) for thickness of the adipose cell layer.
than in control dermis where almost no double-positive cells were
detected.
CSD INHIBITS THE ACCUMULATION OF FIBROCYTES AND CELLS
EXPRESSING CCR5 AND ITS LIGANDS IN FIBROTIC MOUSE DERMIS
In Figure 3, we showed that CSD inhibited dermal thicken-
ing in Pump Model mice. We next determined whether this
beneficial effect is correlated with the reversal of the accu-
mulation of fibrocytes and of cells expressing CCR5 and its
ligands. In addition to inhibiting fibrosis and lipodystrophy
(Figure 3), CSD also completely inhibited the accumulation of
cells double-positive for Procollagen I and CD45, Procollagen
I and CCR5, or CD45 and CCR5 (i.e., fibrocytes, Figure 5)
and of cells double-positive for CCR5 ligands and CD45
(Figure 7). These results support the idea that the beneficial
effect of CSD on dermal fibrosis may be due to the inhi-
bition of the recruitment into the dermis of fibrocytes and
other bone marrow-derived cells that express CCR5 and its
ligands.
CSD INHIBITS THE MIGRATION TOWARD CCR5 LIGANDS OF SSc
MONOCYTES
We next directly evaluated the ability of CSD to inhibit the
recruitment of CCR5-expressing, bone marrow-derived cells. We
previously showed that monocytes from SSc patients are defi-
cient in caveolin-1, are hypermigratory toward the chemokine
CXCL12, and overexpress its receptor CXCR4 (Tourkina et al.,
2011). Treatment with CSD compensated for the caveolin-1
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FIGURE 4 | Increased accumulation of fibrocytes and CCR5-positive cells
in the dermis of SSc patients. Fibrotic and control human skin sections
were stained using the indicated antibodies and DAPI to detect nuclei. Large
numbers of double-positive cells were observed in SSc dermis for each
comparison (A, CCR5 vs. Procol I; C, Procol I vs. CD45; E, CCR5 vs. CD45),
while almost none were observed in Control dermis. These representative
fields were photographed at 400 × magnification. To quantify these
observations, the number of double-positive cells was counted in three
subjects per category, five high power fields (HPF) per subject. The data are
presented in terms of the number of double-positive cells per HPF
(average ± s.e.m.). (B) quantification of (A); (D) quantification of (C); (F)
quantification of (E).
deficiency, thereby inhibiting CXCR4 overexpression and hyper-
migration toward CXCL12. The SSc monocyte phenotype (low
caveolin-1, high CXCR4, hypermigration) could be induced in
control monocytes by treatment with TGF-β.
Analogous to our previous studies, we find that SSc mono-
cytes accumulate high levels of CCR5, are hypermigratory toward
the CCR5 ligands MIP1α and MIP1β, that the accumulation of
CCR5 is inhibited by CSD, and that the hypermigration is totally
blocked by CSD (Figure 8). Similarly, as in our previous stud-
ies, when control monocytes are activated in vitro using TGF-β,
they become hypermigratory toward CCR5 and this migration
is blocked by CSD (Figure 8). Thus, both monocytes activated
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FIGURE 5 | Increased accumulation of fibrocytes and CCR5-positive
cells in fibrotic mouse dermis is reversed by CSD. Mice were treated
with bleomycin and CSD as described in Figure 3. Skin sections were
stained using the indicated antibodies and DAPI to detect nuclei. Large
numbers of double-positive cells were observed in bleomycin-treated mice
(that did not receive CSD) for each comparison (A, CCR5 vs. Procol I; B,
Procol I vs. CD45; C, CCR5 vs. CD45), while almost none were observed
in Control mice. CSD treatment almost completely blocked the
accumulation of these cells. These representative fields were
photographed at 400 × magnification. To quantify these observations, the
number of double-positive cells was counted in three subjects per
category, five HPF per subject. The data are presented in terms of the
number of double-positive cells per HPF (average ± s.e.m.). (D)
quantification of (A); (E) quantification of (B); (F) quantification of (C).
in vivo (SSc) and monocyte activated in vitro (TGF-β) are hyper-
migratory toward CCR5 ligands and this migration is blocked
by CSD.
Given that humanmonocytes from fibrotic subjects are hyper-
migratory toward CCR5 ligands MIP1α and MIP1β and that
this migration is blocked by CSD, we returned to the Pump
Model to determine whether cell migration is also linked to
fibrosis and caveolin-1 in mice. Indeed, bone marrow cells
from bleomycin-treated mice were hypermigratory toward both
MIP1α and MIP1β, and CSD delivered by i.p. injection in vivo
knocked their levels of migration down to the Control mouse
levels (Figure 9). CSD knocked down migration whether it was
administered in vitro to bone marrow cells after their isolation
from bleomycin-treated mice (not shown) or whether it was
administered in vivo to bleomycin-treated mice prior to the isola-
tion of bone marrow cells (Figure 9). These observations strongly
support the idea that CSD inhibits dermal fibrosis by inhibiting
monocyte/fibrocyte recruitment.
CSD PROMOTES THE DIFFERENTIATION OF SUBCUTANEOUS ADIPOSE
CELLS
Figure 3 demonstrates that CSD, in addition to blocking the
thickening of the dermis in bleomycin-treated mice, inhibits the
thinning of the adipose cell layer in these mice and promotes
the thickening of the adipose cell layer in control mice that
did not receive bleomycin. To further understand these effects,
skin sections were double-stained with antibodies against the
adipocyte marker FABP4 and with antibodies against caveolin-1
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FIGURE 6 | Increased accumulation of CCR5 ligand-positive cells in
the dermis of SSc patients. Fibrotic and control human skin
sections were stained using the indicated antibodies and DAPI to
detect nuclei. Large numbers of double-positive cells were observed
in SSc dermis for each comparison (A, MIP1α vs. CD45; C, MIP1β
vs. CD45), while almost none were observed in Control dermis.
These representative fields were photographed at 400 ×
magnification. To quantify these observations, the number of
double-positive cells was counted in three subjects per category, five
HPF per subject. The data are presented in terms of the number
of double-positive cells per HPF (average ± s.e.m.). (B) quantification
of (A); (D) quantification of (C).
which in this context is effectively also an adipocyte marker
(Figure 10). Control mice (saline pump/ PBS injection) showed
punctate and partial ring adipocyte membrane staining for both
FABP4 and caveolin-1 that almost perfectly coincided. When
saline pump mice received CSD injections, FABP4 and caveolin-1
staining were both enhanced, appearing as bright, ring stain-
ing of the entire adipocyte membrane. In bleomycin pump mice
receiving PBS injections, in accord with the fact that by histo-
logical staining there was essentially no adipose cell layer, there
was also almost no FABP4 or caveolin-1 staining. Finally, in
bleomycin pump mice receiving CSD, bright, coincident ring
staining for FABP4 and caveolin-1 was again observed. However,
the diameter of these adipocytes was less than half the diam-
eter of adipocytes in mice that did not receive bleomycin,
strongly suggesting that these are immature adipocytes that are
in the process of filling the void in the adipose cell layer cre-
ated by bleomycin treatment. In any case, the effects of CSD
on mice that received bleomycin and mice that did not receive
bleomycin suggest that CSD promotes adipocyte differentiation
in vivo.
DISCUSSION
In the current study, we have combined a mouse model for fibro-
sis that we have recently characterized (Lee et al., 2014) that
closely models human SSc with our ongoing work on fibrocytes
(CD45+, Collagen+ cells) in fibrosis and on caveolin-1 in fibro-
sis. In this model (Pump Model) fibrosis is observed in the skin
and internal organs in addition to the lungs. We report here that
treatment of Pump Model mice with CSD inhibits dermal fibro-
sis and at the same time inhibits the accumulation in the dermis
of CD45+ cells expressing collagen, CCR5, and the CCR5 ligands
MIP1α and MIPβ. Strongly supporting the idea that the benefi-
cial effect of CSD results from the inhibition of the recruitment
of bone marrow-derived cells into the dermis, we demonstrate
that the migration of bone marrow cells toward CCR5 ligands
is greatly enhanced in Pump Model mice receiving bleomycin
to induce fibrosis compared to vehicle controls and that this
enhanced migration is almost completely blocked in CSD-treated
mice. The relevance of these observations to human disease is
validated by the observations that CD45+ cells expressing col-
lagen, CCR5, and CCR5 ligands are also present at high levels in
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FIGURE 7 | Increased accumulation of CCR5 ligand-positive cells in
fibrotic mouse dermis is reversed by CSD. Mice were treated with
bleomycin and CSD as described in Figure 3. Skin sections were
stained using the indicated antibodies and DAPI to detect nuclei. Large
numbers of double-positive cells were observed in bleomycin-treated
mice (that did not receive CSD) for each comparison (A, MIP1α vs.
CD45; B, MIP1β vs. CD45), while almost none were observed in
Control mice. CSD treatment almost completely blocked the
accumulation of these cells. These representative fields were
photographed at 400 × magnification. To quantify these observations,
the number of double-positive cells was counted in three subjects per
category, five HPF per subject. The data are presented in terms of the
number of double-positive cells per HPF (average ± s.e.m.). (C)
quantification of (A); (D) quantification of (B).
the dermis of SSc patients, that SSc monocytes overexpress CCR5,
and that the hypermigration of SSc monocytes toward CCR5 lig-
ands is blocked by CSD treatment. Strongly supporting the idea
that the beneficial effect of CSD results from the inhibition of
the recruitment of bone marrow-derived cells into the dermis,
we have recently observed (manuscript in preparation) that the
migration toward several different chemokines of Pump Model
mouse bonemarrow cells is greatly enhanced compared to control
mice bone marrow cells and that this enhanced migration is com-
pletely blocked when mice are treated with CSD in addition to
bleomycin. Finally, we made the unexpected observation that in
PumpModel mice dermal thickening is accompanied by thinning
of the subcutaneous adipocyte cell layer and that CSD treatment,
in addition to inhibiting the thickening of the dermis, inhibits the
thinning of the adipocyte cell layer.
Most work on CCR5 has been performed in the context
of human immunodeficiency virus infection/acquired immun-
odeficiency syndrome (HIV/AIDS) research. CCR5 serves as a
co-receptor for the entry of HIV into T cells (Steffens and Hope,
2004). People carrying the CCR5 32 mutation express little if
any CCR5 at the cell surface and are resistant to HIV infection and
may also be protected against bubonic plague (Liu et al., 1996;
Samson et al., 1996). Interestingly, another chemokine receptor,
CXCR4, that has been implicated in the regulation of fibrosis also
serves as anHIV co-receptor.We find that both CCR5 (this paper)
and CXCR4 (Tourkina et al., 2010, 2011) are overexpressed on
SSc monocytes leading to their hypermigration toward cognate
ligands. In both cases, CSD blocks this hypermigration.
The internalization of chemokine receptors plays an important
role in ligand-induced cellular responses. After internalization,
receptors can either be recycled back to the plasma membrane
to be re-exposed to ligands or are trafficked for degradation.
In the case of TGF-β receptors, caveolae-mediated internaliza-
tion results in rapid turnover, thereby inhibiting TGF-β signaling
(Di Guglielmo et al., 2003). If a similar mechanism applies
to CCR5 and CXCR4, then the low level of caveolin-1 in SSc
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FIGURE 8 | The hypermigration of SSc monocytes and TGF-β-treated
Control monocytes toward CCR5 ligands is regulated by caveolin-1.
(A) Migration experiments were performed as described in the Methods
using Control or SSc monocytes. Cells were treated with TGF-β and CSD as
indicated. Lower wells contained 100 nM of MIP1α or MIP1β. Cells that had
migrated were counted in six high power fields per filter. Note that for both
MIP1α and MIP1β, the induction of migration was extremely enhanced in
both SSc monocytes and TGF-β-treated Control monocytes compared to
untreated Control monocytes and that in both cases CSD completely blocked
the enhanced migration. The data represent the average ± s.e.m. from four
independent experiments using cells from different subjects. (B) CCR5 level
is increased in SSc monocytes; (C) CSD decreases the level of CCR5 in SSc
monocytes. Control and SSc monocytes were isolated as described in the
Methods. SSc monocytes were treated with CSD as previously described
(Tourkina et al., 2010). For Western blotting experiments, cells were extracted
with boiling SDS-PAGE Sample Buffer. In (B), the Western blot of a typical
experiment shows a large increase in the level of CCR5 in SSc monocytes
compared to Control monocytes and no change in the level of the loading
control GAPDH. In (C), the Western blot of a typical experiment shows that
CSD treatment decreases the level of CCR5 in SSc monocytes without
affecting GAPDH. The densitometric quantifications in (B,C) show the
average ± s.e.m. in arbitrary units for four repeats of each experiment
performed with cells from different subjects. The Control value in (B) and the
CSD minus value in (C) are set to 1 arbitrary unit.
FIGURE 9 | Bone marrow cells from bleomycin-treated mice are
hypermigratory toward CCR5 ligands and this migration is blocked by
CSD. Migration experiments were performed as described in the Methods
using bone marrow cells from mice treated with bleomycin or saline
vehicle. Mice were treated with CSD as indicated. Lower wells contained
100 ng/ml of MIP1α or MIP1β. Cells that had migrated were counted in six
high power fields per filter. Note for both MIP1α and MIP1β, that the
induction of migration was extremely enhanced in bone marrow cells from
bleomycin-treated mice compared to bone marrow cells from
vehicle-treated mice and that CSD completely blocked the enhanced
migration. The data represent the average ± s.e.m. from three independent
experiments using cells from different subjects.
monocytes may result in the overexpression of CCR5 and CXCR4
in SSc monocytes due to a deficit in turnover. In considering the
molecular mechanism underlying the accumulation of CCR5 in
scleroderma monocytes and its reversal by CSD, it is interesting
to note that CCR5 is a G protein-coupled receptor (Oppermann,
2004) and that caveolin-1 is known to bind to and modulate the
function of G proteins (Li et al., 1995). While the significance to
the current study remains to be determined, it is also noteworthy
that the level of CCR5 onSSc-ILD and IPF T cells is low compared
to control T cells (Capelli et al., 2005; Boin et al., 2008).
While CCR5 and its ligands have been studied in the context
of lung fibrosis (Ishida et al., 2007), to the best of our knowl-
edge, this is the first study of CCR5 in skin fibrosis. Our results are
consistent with those of Ishida et al. who showed that bleomycin-
induced fibrosis, fibrocyte recruitment, and inflammatory cell
recruitment in general were blocked both in CCR5 and MIP1α
(also known as CCL3) KOmice. Thus inhibition of the CCR5 axis
may be a universal treatment for fibrotic diseases.
Skin fibrosis in SSc is associated with loss of subcutaneous adi-
pose tissue (lipodystrophy) (Marangoni et al., 2012). Similarly, we
observed a loss of subcutaneous adipose tissue concomitant with
dermal fibrosis in the Pump Model, both of which were blocked
by CSD. These observations are consistent with the fact that
caveolin-1 KO mice are lean with small adipocytes (Razani et al.,
2002). The mechanisms underlying lipodystrophy and its rela-
tionship to fibrosis are not known, but may involve regulation by
caveolin-1 of the ability of pluripotent cells to differentiate either
into myofibroblasts or adipocytes. Whether these cells might be
monocytes, fibrocytes, or stem cells is an open question. This issue
should be of great current interest in the treatment of SSc because
stem cell therapy is receiving intense scrutiny as a treatment for
several diseases including SSc, diabetes, rheumatoid arthritis, and
lupus, and, indeed, limited promising results have already been
www.frontiersin.org June 2014 | Volume 5 | Article 140 | 11
Lee et al. Caveolin-1 regulates CCR5-mediated dermal fibrosis
FIGURE 10 | FABP4/Caveolin-1 double staining of the adipocyte
layer of mice treated with bleomycin and CSD. Sections from the
indicated mice were stained using the indicated antibodies and DAPI
to detect nuclei. Staining at the level of the adipocyte layer is
shown.. These representative fields were photographed at 400 ×
magnification. Observations are described in detail in the text. Similar
results were obtained in three independent experiments using cells
from different subjects.
obtained (Mizuno, 2010; Tyndall, 2011). Also noteworthy in con-
templating the relationship betweenlipodystrophy and fibrosis are
the observations that the level of the adipocyte-produced cytokine
adiponectin is reducedin the serum and skin of SSc patients and
that adiponectin has anti-fibrotic effects including the inhibition
of collagen expression by fibroblasts (Arakawa et al., 2011; Fang
et al., 2012; Lakota et al., 2012).
Another interesting potential mechanism for the loss of
adipocytes in fibrotic tissue is that the rigid matrix has a variety
of negative effects on adipocytes (Sun et al., 2013). In any case,
because the mix of cells in the adipose layer is complex and their
functions are many (Rosen and Spiegelman, 2014), it is likely that
the relationship between fibrosis and adipogenesis will be com-
plicated and important to the understanding and treatment of a
wide range of diseases including not only fibrotic diseases, but
also, diabetes, obesity, and wound healing.
In summary, the current studies provide novel information on
the regulation of dermal fibrosis by caveolin-1 via its effects on the
expression and function of CCR5 on monocytes and fibrocytes,
the recruitment of fibrocytes and/or their progenitors into the
affected tissue, and the thickness of the adipose cell layer in
fibrotic tissue. In addition, these studies further validate CSD as
a potential treatment for fibrotic diseases of the skin and other
organs.
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